Buprenorphine-Naloxone Telepsychiatry

Evidence-Based Initiation and Management for Opioid Use Disorder

Tele-MAT OUD Treatment Evidence-Based 2026 Update

Executive Summary

Telehealth-based medication-assisted treatment (MAT) for opioid use disorder has demonstrated retention rates equal to or superior to traditional in-person care. Studies show 83% of telehealth patients complete urine drug screening within 30 days of initiation, with comparable outcomes across clinical and psychosocial measures.

Key Evidence

66-80% reduction in overdose death risk with buprenorphine treatment
Tele-MAT retention rates ≥ in-person care
<1% precipitated withdrawal when protocols followed (even with fentanyl)

Critical Success Factors

Rigorous patient selection using established suitability criteria
Flexible induction protocols (standard vs. micro-dosing)
Robust safety planning with comprehensive emergency protocols
Integrated psychosocial support leveraging digital resources
Compliance with evolving regulatory requirements

Patient Selection for Tele-MAT

Ideal Candidate Profile

Clinical Stability

Moderate to severe OUD with documented dependence
Ability to self-administer medication safely
High motivation for recovery and treatment engagement

Psychosocial Readiness

Stable housing with reliable address for emergency services
Supportive home environment or family support system
Understanding of withdrawal symptoms and medication effects

Technical Competency

Access to reliable technology (smartphone, tablet, computer)
Ability to navigate video conferencing platforms
Willingness to participate in regular virtual check-ins

Contraindications

Absolute Contraindications (Require In-Person Care)

Severe polysubstance use disorder requiring intensive medical supervision
No access to phone or internet technology
Active psychosis or severe mental illness requiring immediate psychiatric intervention
Recent overdose within 48 hours requiring medical evaluation
Severe medical comorbidities requiring frequent in-person monitoring

Relative Contraindications (Require Enhanced Monitoring)

Active benzodiazepine use (requires careful coordination)
Unstable psychiatric comorbidities (severe depression with SI)
History of medication diversion (may benefit from electronic pill dispensing)
Mild cognitive impairment affecting ability to follow instructions

The Initial Virtual Consultation

Technology Check

→

Rapport Building

→

Substance Use History

→

Mental Health Screen

→

Safety Assessment

Critical Documentation Requirements

Domain	Required Elements
Substance Use	Primary opioid (short vs. long-acting), last use timing, daily patterns, route, previous treatment attempts, precipitated withdrawal history
Polysubstance	Alcohol, benzodiazepines, stimulants, cannabis, nicotine
Mental Health	PTSD, MDD, anxiety, bipolar, psychotic disorders, suicide risk assessment
Environment	Physical safety, medication security, emergency contacts, support system

Patient Education Script — Key Points

"Today we're going to discuss starting buprenorphine treatment from your home. This medication is highly effective—studies show it can reduce your risk of overdose death by 66-80%. The most important rule is complete honesty about when you last used opioids. We'll use the COWS scale to determine when you're ready. You need to wait until you're experiencing moderate withdrawal symptoms before taking your first dose."

Buprenorphine-Naloxone Induction

Standard Home Induction Protocol

Day	Timing	Dose	Instructions
Day 1	Morning	2mg SL	Confirm COWS ≥11-13; no eating/drinking 30 min after
Day 1	+30-60 min	+2mg if needed	Virtual check-in for withdrawal relief
Day 1	Maximum	8mg total	Avoid exceeding to prevent precipitated withdrawal
Day 2	Morning	8mg once daily	+2mg q2h PRN; max 16mg
Day 3+	Target	12-16mg daily	Titrate by 2-4mg daily based on symptoms

Micro-dosing Induction (Bernese Method)

Indications for Micro-dosing

Fentanyl users (70% of current OUD population)
Long-acting opioids (methadone, extended-release)
Previous precipitated withdrawal
Unable to tolerate withdrawal symptoms
Time-sensitive situations (hospitalized patients)

Day	Buprenorphine Dose	Full Agonist	Instructions
1	0.5mg once daily	Continue full dose	Take buprenorphine 2 hours after opioid use
2	0.5mg BID	Continue full dose	Space doses 12 hours apart
3	1mg BID	Continue full dose	Monitor for withdrawal symptoms
4	2mg BID	Reduce 25%	Begin tapering full agonist
5	3mg BID	Reduce 50%	Assess comfort frequently
6	4mg BID	Reduce 75%	Prepare for discontinuation
7	8mg once daily	STOP	Transition to standard maintenance

Clinical Opiate Withdrawal Scale (COWS)

Target Score: 11-13 for standard induction (moderate withdrawal)

Managing Precipitated Withdrawal

Emergency Protocol — Precipitated Withdrawal

Step 1: Rapid video assessment within 15 minutes — COWS score, vital signs if available

Step 2: Supportive care — hydration (8-12 oz/hour), cool cloths, reassurance ("This will pass, typically peaks in 2-4 hours")

Step 3: Symptomatic relief — Imodium 2mg for diarrhea; Acetaminophen 650mg for muscle aches; Hydroxyzine 25-50mg for anxiety (if prescribed)

Step 4: DO NOT give additional buprenorphine initially — monitor every 30 minutes

ED Criteria: Severe dehydration, HR >140 bpm, chest pain, severe psychiatric symptoms, or patient request

Remote Monitoring Best Practices

Remote Urine Drug Screening

Studies demonstrate 83% compliance with remote UDS within 30 days and 99.7% compliance within 180 days of telehealth MAT initiation.

Self-Collection Kits

Mail-order with temperature strips and adulteration testing. Chain of custody documentation.

Video-Supervised Collection

Identity verification, visual sample inspection, privacy protocols.

DNA Verification

Genetic matching of patient to sample; eliminates need for viewed collection.

Virtual Pill Count Procedures

Electronic pill dispensers with automated dispensing and tamper detection
Video-supervised counts with bottle identification verification
Mobile app integration for daily check-ins and adherence tracking
Scheduled weekly or monthly virtual counts

Regulatory & Safety Planning

Current Federal Regulations (2025)

Ryan Haight Act Flexibilities extended through December 31, 2025
Buprenorphine prescribing via telehealth without prior in-person visit permitted
Audio-only visits for Schedule III-V medications including buprenorphine
Six-month initial supply for qualified practitioners

Mandatory Safety Plan Components

Emergency Contacts: Primary, secondary, healthcare proxy, pharmacy contacts
Medical Emergency Protocols: Nearest ED, overdose response plan, naloxone availability
Mental Health Crisis Plan: 988 Suicide Lifeline, local crisis intervention, personalized warning signs
Precipitated Withdrawal Protocol: Provider 24/7 contact, self-care instructions, ED criteria
Medication Management: Secure storage, lost/stolen protocol, drug interactions
Communication Protocols: Preferred contact method, response time expectations, after-hours coverage

Clinical Tools & Quick Reference

Dosing Conversion

Short-acting opioids: Wait 8-16 hours

Long-acting opioids: Wait 24-36 hours

Fentanyl: Consider micro-dosing

Target Dosing

Maintenance: 12-16mg daily

Max Day 1: 8mg

Titration: +2-4mg daily

Follow-up Schedule

Days 1-7: Daily contact

Weeks 2-4: Twice weekly

Month 2+: Monthly

Key Clinical Pearls

Tele-MAT retention rates equal or exceed in-person care
<1% precipitated withdrawal when protocols followed
Micro-dosing indicated for fentanyl users
COWS ≥11-13 target for standard induction
Split dosing often needed for methadone in 3rd trimester
Remote UDS: 83% compliance at 30 days, 99.7% at 180 days